Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Stock Short Interest Climbs 11,467.5%

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) was the target of a large growth in short interest during the month of September. As of September 15th, there was short interest totaling 31,478,314 shares, a growth of 11,467.5% from the August 31st total of 272,128 shares. Approximately 2.7% of the shares of the company are short sold. Based on an average trading volume of 1,150,992 shares, the days-to-cover ratio is presently 27.3 days.

Trending Headlines about Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Oppenheimer initiated coverage with an “Outperform” rating and a $50 price target, implying meaningful upside from recent trading levels. The firm reportedly views Teva as entering an acceleration phase supported by a multi-year product-launch cycle, although it cited some near-term concerns around Austedo. Oppenheimer Teva coverage article
• Positive Sentiment: Teva’s investigational once-monthly olanzapine long-acting injectable, TEV-749, and its UZEDY schizophrenia treatment remain potential growth drivers. Recent clinical data support investor interest in Teva’s central-nervous-system franchise, though TEV-749 still requires regulatory approval. Teva pipeline update
• Neutral Sentiment: Teva released its Q3 2026 aide memoire and confirmed that third-quarter results will be issued on November 3 before an investor conference call. The materials provide an upcoming catalyst, but do not themselves contain new financial results or guidance. Teva Q3 2026 aide memoire
• Neutral Sentiment: The stock is approximately 4.36% below its yearly high, indicating strong recent momentum but also leaving investors focused on whether upcoming earnings can justify the elevated valuation. Teva stock near yearly high
• Negative Sentiment: Director Roberto Mignone sold 367,600 shares for approximately $14.36 million. The large sale, made after a significant advance in TEVA, could create near-term selling pressure and raise questions about insider confidence. SEC filing for Roberto Mignone share sale
• Negative Sentiment: Interim Chief Legal Officer Brian Savage separately sold 7,342 shares worth about $285,000, reducing his direct ownership by roughly 46%. The additional insider sale reinforces the caution surrounding TEVA’s recent rally. Teva insider selling report

Teva Pharmaceutical Industries Stock Up 3.0%

Shares of NYSE:TEVA traded up $1.17 during trading on Thursday, reaching $40.18. 7,730,889 shares of the stock were exchanged, compared to its average volume of 6,865,927. Teva Pharmaceutical Industries has a 1-year low of $18.21 and a 1-year high of $40.79. The firm has a market cap of $46.82 billion, a price-to-earnings ratio of 66.97, a price-to-earnings-growth ratio of 4.93 and a beta of 0.87. The stock has a fifty day moving average of $35.88 and a two-hundred day moving average of $33.70. The company has a debt-to-equity ratio of 1.56, a current ratio of 0.88 and a quick ratio of 0.67.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Tuesday, June 30th. The company reported $0.02 earnings per share (EPS) for the quarter. The firm had revenue of $4.14 billion during the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.64%. Research analysts anticipate that Teva Pharmaceutical Industries will post 1.94 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on TEVA. Piper Sandler increased their price target on Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 28th. Oppenheimer initiated coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday. They issued an “outperform” rating and a $50.00 price objective for the company. UBS Group upped their price objective on Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the company a “buy” rating in a research note on Friday, September 4th. Leerink Partners began coverage on Teva Pharmaceutical Industries in a research report on Wednesday, September 9th. They set an “outperform” rating and a $45.00 target price for the company. Finally, Wall Street Zen downgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Eleven research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $43.73.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, insider Brian Savage sold 7,342 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, September 18th. The stock was sold at an average price of $38.85, for a total transaction of $285,236.70. Following the completion of the sale, the insider directly owned 8,500 shares of the company’s stock, valued at approximately $330,225. This trade represents a 46.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Roberto Mignone sold 367,600 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, September 18th. The stock was sold at an average price of $39.06, for a total value of $14,358,456.00. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 374,959 shares of company stock worth $14,644,285. Corporate insiders own 0.54% of the company’s stock.

Institutional Trading of Teva Pharmaceutical Industries

Institutional investors and hedge funds have recently modified their holdings of the business. Legal & General Group Plc boosted its holdings in shares of Teva Pharmaceutical Industries by 6.8% in the 4th quarter. Legal & General Group Plc now owns 3,608,387 shares of the company’s stock worth $112,618,000 after buying an additional 228,189 shares during the last quarter. Norges Bank purchased a new position in shares of Teva Pharmaceutical Industries in the fourth quarter worth about $1,098,060,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Teva Pharmaceutical Industries during the 1st quarter valued at approximately $9,126,000. TD Asset Management Inc grew its stake in Teva Pharmaceutical Industries by 47.1% in the 4th quarter. TD Asset Management Inc now owns 369,023 shares of the company’s stock valued at $11,517,000 after buying an additional 118,075 shares in the last quarter. Finally, WCM Investment Management LLC increased its position in shares of Teva Pharmaceutical Industries by 191.4% during the first quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company’s stock valued at $1,157,264,000 after buying an additional 26,813,522 shares during the period. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. The company develops, manufactures and markets generic medicines, innovative specialty medicines, biosimilars, over-the-counter products and active pharmaceutical ingredients. Its portfolio serves a broad range of therapeutic areas, including central nervous system disorders, respiratory conditions, migraine, oncology and movement disorders.

Teva’s specialty medicines include treatments for conditions such as multiple sclerosis, migraine and tardive dyskinesia, while its generic medicines business supplies products across numerous therapeutic categories and dosage forms.